Search

Displaying results 3651 - 3660 of 4238 in total
  1. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    The lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism of lipids, and its absence or deficiency results in the accumulation of lipids in various organs. This lipid accumulation can le...

  2. Drug

    SB-269970

    go.drugbank.com/drugs/DB13988
    Experimental

    In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).[A31816,A31817]

  3. Drug

    Canosimibe

    go.drugbank.com/drugs/DB19723
    Investigational

    Canosimibe is under investigation in clinical trial NCT00729027 (Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia).

  4. Drug

    Nitrocefin

    go.drugbank.com/drugs/DB11592
    Experimental

    While other detection methods exist, such as PCR, nitrocefin allows for rapid detection using few materials and inexpensive equipment.

  5. Drug

    Drozitumab

    go.drugbank.com/drugs/DB19106
    Investigational

    It was developed by Genentech as a drug for the treatment of cancers

  6. Drug

    Tralesinidase alfa

    go.drugbank.com/drugs/DB17657
    Investigational

    It is being investigated for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome B.[A258828]

  7. Drug

    Racivir

    go.drugbank.com/drugs/DB12753
    Investigational

    Racivir, also known as RCV, is an oxothiolane nucleoside reverse transcriptase inhibitor similar to emtricitabine and lamivudine.

  8. Drug

    TC-5231

    go.drugbank.com/drugs/DB05333
    Experimental

    TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder).

  9. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Tividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099

  10. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    [L64095,L64118] It is given as an intramuscular injection into the corrugator and procerus muscles, is intended for occasional use, and its potency units are not interchangeable with those of other botulinum